Kyverna Therapeutics, Inc. (KYTX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $668.56M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-142.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $660.23M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-96.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $657.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $97.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $538.94M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $29.00K.
Kyverna Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | $668.56M | $-142.00K | $-502.87M | $165.55M | (m) | 3 month · $3.51M |
| 2026-03-31 | $0.00 | $1.00K | $660.23M | $-96.00K | $-464.56M | $195.58M | (m) | 3 month · $3.17M |
| 2025-12-31 | $0.00 | $1.00K | $657.00M | $97.00K | $-424.83M | $232.28M | 12 month · $6.59M | 12 month · $10.08M |
| 2025-09-30 | (m) | (m) | $538.94M | $29.00K | $-387.02M | $151.95M | (m) | 3 month · $2.70M |
| 2025-06-30 | (m) | (m) | $534.63M | $-20.00K | $-350.24M | $184.38M | (m) | 3 month · $2.52M |
| 2025-03-31 | (m) | (m) | $532.17M | $-1.00K | $-308.15M | $224.01M | (m) | 3 month · $2.16M |
| 2024-12-31 | $0.00 | $0.00 | $530.00M | $105.00K | $-263.52M | $266.59M | 12 month · $30.69M | 12 month · $8.36M |
| 2024-09-30 | (m) | (m) | $528.59M | $153.00K | $-226.03M | $302.71M | (m) | 3 month · $3.41M |
| 2024-06-30 | (m) | (m) | $525.09M | $-37.00K | $-191.54M | $333.51M | (m) | 3 month · $1.28M |
| 2024-03-31 | (m) | (m) | $523.73M | $-1.00K | $-162.74M | $360.99M | 3 month · $30.69M | 3 month · $2.28M |
| 2023-12-31 | (m) | (m) | $4.64M | $4.00K | $-136.04M | $-13.14M | 12 month · $100.00K | 12 month · $2.22M |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $-111.81M | 3 month · $49.00K | 3 month · $521.00K |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-97.19M | 3 month · $51.00K | 3 month · $447.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-84.61M | (m) | 3 month · $468.00K |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $-74.00M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |